🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Rory M. Shallis

Yale Cancer Center

ORCID: 0000-0002-8542-2944

Also affiliated with Moffitt Cancer Center

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 14 papers. Top paper: “A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents”.

A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents

Annals of Hematology(2023)10.1007/s00277-023-05552-4
N/A
0.726DataRank · unranked
23 citations

Rory M. Shallis, Elad Sharon, Silvia Park, Rahul Ramaswamy, Caroline E. Roe +18 more

Epidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex map

Blood Reviews(2020)10.1016/j.blre.2020.100706
N/A
0DataRank · unranked
85 citations

Rong Wang, Amy J. Davidoff, Xiaomei Ma, Nikolai A. Podoltsev, Amer M. Zeidan +1 more

Practice patterns and real-life outcomes for patients with acute promyelocytic leukemia in the United States

Blood Advances(2021)10.1182/bloodadvances.2021005642
N/A
0DataRank · unranked
12 citations

Stephanie Prozora, Nikolai A. Podoltsev, Rory M. Shallis, Scott F. Huntington, Natalia Neparidze +4 more

Azacitidine maintenance after allogeneic hematopoietic cell transplantation for MDS and AML

Blood Advances(2021)10.1182/bloodadvances.2020003839
N/A
0DataRank · unranked
9 citations

Uma Borate, Rémy Duléry, Shernan G. Holtan, Arjun Law, Lori Muffly +8 more

Challenges in the Evaluation and Management of Toxicities Arising From Immune Checkpoint Inhibitor Therapy for Patients With Myeloid Malignancies

Clinical Lymphoma Myeloma & Leukemia(2021)10.1016/j.clml.2021.01.003
N/A
0DataRank · unranked
1 citations

Jan Philipp Bewersdorf, David M. Swoboda, Wei Wei, Lohith Gowda, Thomas Prébet +10 more

TP53‐altered acute myeloid leukemia and myelodysplastic syndrome with excess blasts should be approached as a single entity

Cancer(2022)10.1002/cncr.34535
N/A
0DataRank · unranked
17 citations

Naval Daver, Jessica K. Altman, Robert P. Hasserjian, Hagop M. Kantarjian, Uwe Platzbecker +5 more

Cost-effectiveness of liposomal cytarabine/daunorubicin in patients with newly diagnosed acute myeloid leukemia

Blood(2022)10.1182/blood.2021014401
N/A
0DataRank · unranked
11 citations

Kishan Patel, George Goshua, Rory M. Shallis, Nikolai A. Podoltsev, Scott F. Huntington +2 more

Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Blood Cancer Journal(2024)10.1038/s41408-024-01000-2
N/A
0DataRank · unranked
31 citations

Ahmad Nanaa, Ehab Atallah, Rory M. Shallis, Sacchi de Camargo Correia Guilherme, Aaron D. Goldberg +12 more

Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AML

Blood Advances(2024)10.1182/bloodadvances.2024012858
N/A
0DataRank · unranked
12 citations

Shai Shimony, Rory M. Shallis, Yiwen Liu, Guillaume Berton, Eva J. Schaefer +18 more

Real‐world outcomes of intensive induction approaches in core binding factor acute myeloid leukemia

eJHaem(2024)10.1002/jha2.981
N/A
0DataRank · unranked
10 citations

Benjamin J. McCormick, Joanna Cwykiel, Oluwatobi Odetola, Yasmin Abaza, Nhi Nai +10 more

Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1‐ or IDH2‐mutant newly diagnosed acute myeloid leukemia—A multicenter cohort study

American Journal of Hematology(2024)10.1002/ajh.27366
N/A
0DataRank · unranked
9 citations

Shai Shimony, Rory M. Shallis, Yiwen Liu, Guillaume Berton, Eva J. Schaefer +18 more

Evaluating the impact of stratification on the power and cross-arm balance of randomized phase 2 clinical trials

Clinical Trials(2025)10.1177/17407745241304065
N/A
0DataRank · unranked
2 citations

Michael LeBlanc, Boris Freidlin, Rory M. Shallis, Amer M. Zeidan, David A. Sallman +4 more

Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts

The Lancet Haematology(2020)10.1016/s2352-3026(20)30205-2
N/A
0DataRank · unranked
97 citations

Prajwal Boddu, Mrinal M. Patnaik, Jan Philipp Bewersdorf, Maximilian Stahl, Raajit K. Rampal +47 more

Second malignancies among older patients with classical myeloproliferative neoplasms treated with ruxolitinib

Blood Neoplasia(2025)10.1016/j.bneo.2025.100159
N/A
0DataRank · unranked
0 citations

Jessica M. Stempel, Rory M. Shallis, Scott F. Huntington, Amer M. Zeidan, Natalia Neparidze +6 more